# PregLem

Source: https://onco.cc/companies/preglem/  
OnCo record `preglem` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PregLem is a Geneva biotech, part of Gedeon Richter, whose ulipristal acetate (Esmya) for uterine fibroids went through phase 3 trials it led; it is listed among industry sponsors of cancer-tagged trials.

## Summary

PregLem SA, founded in Geneva in 2006 and later acquired by the Hungarian group Gedeon Richter, developed ulipristal acetate (Esmya) for the treatment of uterine fibroids, a benign gynaecological tumour. Its phase 3 programme is registered on ClinicalTrials.gov, where the trials fall under the cancer and neoplasm categories that OnCo's sponsor list draws on.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: PregLem SA; PregLem S.A.
- Tags: ctgov-sponsor
- HQ: Geneva
- Type: biotech
- Website: http://preglem.com

## Sources

- Official website: http://preglem.com
- ClinicalTrials.gov: trials led by PregLem SA: https://clinicaltrials.gov/search?lead=PregLem%20SA
- Wikidata: https://www.wikidata.org/wiki/Q30269207

## Connected records

- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/preglem.json